For this pharmacological validation, a panel of enzymes were chosen whereby α-amylase and α-glucosidase are used for DM type 2, AChE and BChE for AD, tyrosinase and elastase for cutaneous manifestations and pancreatic lipase for obesity. The gene discussed is PNLIP; the disease is obesity due to melanocortin 4 receptor deficiency.